Safety and immunogenicity of a live-attenuated influenza virus vector-based intranasal SARS-CoV-2 vaccine in adults: randomised, double-blind, placebo-controlled, phase 1 and 2 trialsFengcai Zhu, Ningshao Xia, Chunlan Zhuang et al.|The Lancet Respiratory Medicine|2022Cited by 140
Long-term efficacy of a recombinant hepatitis E vaccine in adults: 10-year results from a randomised, double-blind, placebo-controlled, phase 3 trialShoujie Huang, Ningshao Xia, Xiaohui Liu et al.|The Lancet|2024Cited by 70
Immunogenicity and safety of an Escherichia coli-produced human papillomavirus (types 6/11/16/18/31/33/45/52/58) L1 virus-like-particle vaccine: a phase 2 double-blind, randomized, controlled trialYuemei Hu, Ningshao Xia, Zhaofeng Bi et al.|Science Bulletin|2023Cited by 26
Active surveillance of hepatitis E: a 10-year epidemiological analysis in a city in eastern ChinaXingcheng Huang, Ningshao Xia, Xiaoxiang Zheng et al.|Emerging Microbes & Infections|2024Cited by 11
Long-term protection from naturally acquired immunity against hepatitis E virus reinfectionXiaohui Liu, Ningshao Xia, Xia Zang et al.|Nature Communications|2025Cited by 0